Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: August 17, 2017
What is the competitive landscape for BAUSCH AND LOMB, and what generic alternatives to BAUSCH AND LOMB drugs are available?
BAUSCH AND LOMB has seventy-five approved drugs.| Patents: | 22 |
| Tradenames: | 64 |
| Ingredients: | 53 |
| NDAs: | 75 |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch And Lomb | OPTIPRANOLOL | metipranolol hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019907-001 | Dec 29, 1989 | AT | RX | Yes | Yes | ► Subscribe | ► Subscribe | ► Subscribe | |||||||||||||||||
Bausch And Lomb Inc | LOTEMAX | loteprednol etabonate | GEL;OPHTHALMIC | 202872-001 | Sep 28, 2012 | RX | Yes | Yes | ► Subscribe | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
Bausch And Lomb | ISTALOL | timolol maleate | SOLUTION/DROPS;OPHTHALMIC | 021516-001 | Jun 4, 2004 | AT2 | RX | Yes | Yes | ► Subscribe | ► Subscribe | Y | ► Subscribe | ||||||||||||||||
Bausch And Lomb | DIPIVEFRIN HYDROCHLORIDE | dipivefrin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 074188-001 | May 19, 1995 | DISCN | No | No | ► Subscribe | ► Subscribe | ► Subscribe | ||||||||||||||||||
Bausch And Lomb | PENTOLAIR | cyclopentolate hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 040075-001 | Apr 29, 1994 | AT | RX | No | No | ► Subscribe | ► Subscribe | ► Subscribe | |||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch And Lomb | ZYLET | loteprednol etabonate; tobramycin | SUSPENSION/DROPS;OPHTHALMIC | 050804-001 | Dec 14, 2004 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Bausch And Lomb | LOTEMAX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020583-001 | Mar 9, 1998 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Bausch And Lomb | ALREX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020803-001 | Mar 9, 1998 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Bausch And Lomb | LOTEMAX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020583-001 | Mar 9, 1998 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Bausch And Lomb | BESIVANCE | besifloxacin hydrochloride | SUSPENSION/DROPS;OPHTHALMIC | 022308-001 | May 28, 2009 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
bepotastine besilate | Ophthalmic Solution | 1.5% | BEPREVE | 9/9/2013 |
bromfenac sodium | Ophthalmic Solution | 0.07% | PROLENSA | 7/26/2013 |
timolol maleate | Ophthalmic Solution | 0.5% | ISTALOL | 10/19/2012 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7,732,415 | Topical treatment or prevention of ocular infections | ► Subscribe | |||||||||||||||||||||||||||
| 8,497,304 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid | ► Subscribe | |||||||||||||||||||||||||||
| 8,252,307 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids | ► Subscribe | |||||||||||||||||||||||||||
| 7,282,589 | Acid addition salt of optically active piperidine compound and process for preparing the same | ► Subscribe | |||||||||||||||||||||||||||
| 7,749,970 | Topical treatment of prevention of ocular infections | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Taiwan | 201038536 | ► Subscribe | |||||||||||||||||||||||||||
| Portugal | 1165058 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 2002540147 | ► Subscribe | |||||||||||||||||||||||||||
| China | 1242013 | ► Subscribe | |||||||||||||||||||||||||||
| European Patent Office | 1588702 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C0128 | France | ► Subscribe | PRODUCT NAME: LATANOPROST; REGISTRATION NO/DATE IN FRANCE: NL 22549 DU 19970724; REGISTRATION NO/DATE AT EEC: 12716 DU 19960718 | ||||||||||||||||||||||||||
| C0031 | France | ► Subscribe | PRODUCT NAME: BROMFENAC, SES SELS OU HYDRATES PHARMACOLOGIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/11/692/001 DU 20110518; REGISTRATION NO/DATE AT EEC: EU/1/11/692/001 DU 20110518 | ||||||||||||||||||||||||||
| C0041 | Belgium | ► Subscribe | PRODUCT NAME: LEVOFLOXACINUM HEMIHYDRICUM; NAT. REGISTRATION NO/DATE: 354 IS 370 F3 19980624; FIRST REGISTRATION: GB 134020011 19970606 | ||||||||||||||||||||||||||
| C/GB02/027 | United Kingdom | ► Subscribe | PRODUCT NAME: 2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)-METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE HYDROCHLORIDE (VALGANCICLOVIR HYDROCHLORIDE); REGISTERED: NL RVG 25992 20010920; UK PL 00031/0599 20020425 | ||||||||||||||||||||||||||
| C/GB99/043 | United Kingdom | ► Subscribe | PRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,322 others who get our Drug Patent Expiration Alerts:
